Rates of referral to a cardiologist, which markedly improves cardiovascular outcomes, differ significantly based on nonclinical patient characteristics.
New guidelines and the continuous modification of current policies will be needed in order to establish and maintain an appropriate professional relationship between physicians and pharmaceutical companies.